. . . . . . . . . . . . "a(CHEBI:lipopolysaccharide) -> p(RGD:Cxcl2)" . "Approximately 61,000 statements." . "Copyright (c) 2011-2012, Selventa. All rights reserved." . "BEL Framework Large Corpus Document" . . "1.4" . "LPS exposure caused a significant increase in pro-inflammatory mediators in the lung tissue (Fig. 3 and Table 2). Although resveratrol did not have a general inhibitory effect on proinflammatory mediators, it did cause a dose-related inhibition of TNF-?, IL-1?, MPO, and CINC-1 levels in the lung tissue (Fig. 3 and Table 2). The positive control, budesonide, caused similar dose-related inhibition of all of the pro-inflammatory proteins increased by LPS treatment (Fig. 3 and Table 2)." . . "Selventa" . . . . "2014-07-03T14:30:32.845+02:00"^^ . . .